CRISPR Therapeutics
CRSP
499 hedge funds and large institutions have $6.57B invested in CRISPR Therapeutics in 2021 Q2 according to their latest regulatory filings, with 111 funds opening new positions, 173 increasing their positions, 125 reducing their positions, and 53 closing their positions.
140% more funds holding in top 10
Funds holding in top 10: 5 → 12 (+7)
109% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 53
38% more repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 125
26% more capital invested
Capital invested by funds: $5.2B → $6.57B (+$1.37B)
12% more funds holding
Funds holding: 444 → 499 (+55)
5.89% less ownership
Funds ownership: 56.54% → 50.65% (-5.9%)
14% less call options, than puts
Call options by funds: $514M | Put options by funds: $599M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$141M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$111M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25.7M |
| 4 |
DVF
Discovery Value Fund
Singapore
|
+$22.6M |
| 5 |
HCS
Himension Capital (Singapore)
Singapore
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$127M |
| 2 |
Two Sigma Investments
New York
|
-$86M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$62.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$62.3M |
| 5 |
Morgan Stanley
New York
|
-$42.3M |
CRSP Hedge Fund Activity: Q2 2021 in Review
499 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2021, worth a combined $6.57B — up 26% from $5.2B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new CRSP positions and 53 closed out — a net gain of 58 holders — while 173 added to existing stakes and 125 trimmed.
The largest buyer was Macquarie Group, adding an estimated $141M. The largest seller was Versant Venture Management, cutting an estimated $127M.
- 499 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2021, up from 444 in Q1 2021.
- Funds reported $6.57B of CRISPR Therapeutics stock for Q2 2021, up 26% quarter-over-quarter.
- 111 funds opened new CRISPR Therapeutics positions in Q2 2021 and 53 closed out, a net change of +58 holders.
- The largest CRISPR Therapeutics buyer in Q2 2021 was Macquarie Group, an estimated $141M added.
- The largest CRISPR Therapeutics seller in Q2 2021 was Versant Venture Management, an estimated $127M sold.
Based on aggregated 13F filings for Q2 2021.